top of page

Oncology expert Paul Rennert gives an update on Aleta Biotherapeutics and previews some targets at #ASCO24

Paul Rennert talks about the first four patients who have been dosed in Aleta's clinical trial, as well as previewing targets such as Claudin 18.2 and BCMA at ASCO.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

SAV_Logo_2024.png

At Savills, the Life Sciences Team specializes in helping biotech companies unlock their full potential by aligning real estate strategies with their scientific and business goals. As a leading global commercial real estate advisory firm, we focus exclusively on occupier services and tenant representation, acting as a trusted partner to some of the most innovative companies in the industry.

bottom of page